Ceribell to Participate in the William Blair 46th Annual Growth Stock Conference

About this update from Ceribell, Inc.

[{"type":"image","alt":"Ceribell","displaySize":"","headline":null,"caption":"Ceribell","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/3cc07cfbaa616f81a3c97d674cb67ebe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5BcDVVqeRNWmoYrVX9N3vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/3cc07cfbaa616f81a3c97d674cb67ebe","width":300,"height":300},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/5BcDVVqeRNWmoYrVX9N3vw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMA--/https://media.zenfs.com/en/globenewswire.com/3cc07cfbaa616f81a3c97d674cb67ebe","width":300,"height":300}},"lazy":false},{"type":"text","content":"SUNNYVALE, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 46th Annual Growth Stock Conference in Chicago. The presentation will take place on Wednesday, June 3, 2026, at 9:20 a.m. Pacific Daylight Time / 11:20 a.m. Central Daylight Time.","length":509,"tagName":"p"},{"type":"text","content":"Event: William Blair 46th Annual Growth Stock Conference Date: Wednesday, June 3, 2026Time: 9:20 a.m. PDT / 11:20 a.m. CDT","length":129,"tagName":"p"},{"type":"text","content":"A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.","length":176,"tagName":"p"},{"type":"text","content":"About CeriBell, Inc.Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute-care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA-cleared for detection ...

More updates from Ceribell, Inc.